Abstract
The phenomenon of “difficult sequence” has long frustrated chemists in their efforts to assemble peptides that contain such sequences by solid phase synthesis methods. A variety of remedial measures are available to minimize or even abolish the negative impact of these sequences during synthesis. These include the use of elevated temperatures and stronger acylating reagents. Amyloid-β, a fragment of the amyloid precursor protein, contains 40-43 residues and possesses a C-terminal sequence that is particularly resistant to ready solid phase synthesis making it a “difficult sequence” peptide. This review focuses on approaches to successfully assemble the peptide by both Boc- and Fmoc solid phase synthesis.
Keywords: amyloid, solid phase peptide synthesis
Protein & Peptide Letters
Title: Amyloid-β as a “Difficult Sequence” in Solid Phase Peptide Synthesis
Volume: 11 Issue: 4
Author(s): Anna K. Tickler, Andrew B. Clippingdale and John D. Wade
Affiliation:
Keywords: amyloid, solid phase peptide synthesis
Abstract: The phenomenon of “difficult sequence” has long frustrated chemists in their efforts to assemble peptides that contain such sequences by solid phase synthesis methods. A variety of remedial measures are available to minimize or even abolish the negative impact of these sequences during synthesis. These include the use of elevated temperatures and stronger acylating reagents. Amyloid-β, a fragment of the amyloid precursor protein, contains 40-43 residues and possesses a C-terminal sequence that is particularly resistant to ready solid phase synthesis making it a “difficult sequence” peptide. This review focuses on approaches to successfully assemble the peptide by both Boc- and Fmoc solid phase synthesis.
Export Options
About this article
Cite this article as:
Tickler K. Anna, Clippingdale B. Andrew and Wade D. John, Amyloid-β as a “Difficult Sequence” in Solid Phase Peptide Synthesis, Protein & Peptide Letters 2004; 11 (4) . https://dx.doi.org/10.2174/0929866043406986
DOI https://dx.doi.org/10.2174/0929866043406986 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimers Disease: Progress and Problems
Current Pharmaceutical Design Editorial [Hot Topic:Sleep Medicine (Guest Editor: Salim Surani)]
Current Respiratory Medicine Reviews Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Sense and Sensibility When Prescribing ‘Off-Label’ to Psychiatric Patients
Current Pharmaceutical Design The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Approaches to a Multitargeting Drug Development: First Profiled 3- Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3β
Medicinal Chemistry Intracellular Signaling and Approaches to the Treatment of Schizophrenia and Associated Cognitive Impairment
Current Pharmaceutical Design Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women
Current Alzheimer Research